81 FR 37640 - Certain Recombinant Factor VIII Products

INTERNATIONAL TRADE COMMISSION

Federal Register Volume 81, Issue 112 (June 10, 2016)

Notice is hereby given that the presiding administrative law judge (ALJ) has issued a final initial determination on May 27, 2016, and a recommended determination on remedy and bonding on June 3, 2016. The ALJ found no violation of Section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337). Should the Commission, however, find a violation of Section 337, the ALJ recommends that the Commission issue a limited exclusion order that excludes from importation into the United States certain recombinant factor VIII products manufactured by processes that infringe certain claims of U.S. Patent Nos. 6,100,061 and 8,084,252. The respondents are Novo Nordisk A/S of Bagsvaerd, Denmark, and Novo Nordisk Inc. of Plainsboro, N.J. Upon a finding of a violation, the ALJ further recommends that cease and desist orders issue to respondents and be directed to respondents' domestic inventories. This notice is soliciting public interest comments only from the public. Parties are to file public interest submissions pursuant to 19 CFR 210.50(a)(4) within 30 days from service of the recommended determination.

[Federal Register Volume 81, Number 112 (Friday, June 10, 2016)]
[Notices]
[Pages 37640-37641]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-13688]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-956]


Certain Recombinant Factor VIII Products

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the presiding administrative law 
judge (ALJ) has issued a final initial determination on May 27, 2016, 
and a recommended determination on remedy and bonding on June 3, 2016.
    The ALJ found no violation of Section 337 of the Tariff Act of 
1930, as amended (19 U.S.C. 1337). Should the Commission, however, find 
a violation of Section 337, the ALJ recommends that the Commission 
issue a limited exclusion order that excludes from importation into the 
United States certain recombinant factor VIII products manufactured by 
processes that infringe certain claims of U.S. Patent Nos. 6,100,061 
and 8,084,252. The respondents are Novo Nordisk A/S of Bagsvaerd, 
Denmark, and Novo Nordisk Inc. of Plainsboro, N.J. Upon a finding of a 
violation, the ALJ further recommends that cease and desist orders 
issue to respondents and be directed to respondents' domestic 
inventories.
    This notice is soliciting public interest comments only from the 
public. Parties are to file public interest submissions pursuant to 19 
CFR 210.50(a)(4) within 30 days from service of the recommended 
determination.

FOR FURTHER INFORMATION CONTACT: Ron Traud, Office of the General 
Counsel, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, (202) 205-3427. The public version of the 
complaint can be accessed on the Commission's electronic docket (EDIS) 
at http://edis.usitc.gov, and will be available for inspection during 
official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the 
Secretary, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, (202) 205-2000.
    General information concerning the Commission may also be obtained 
at http://www.usitc.gov. The public record for this investigation may 
be viewed on EDIS at http://edis.usitc.gov. Hearing-impaired persons 
can obtain information on this matter by contacting the Commission's 
TDD terminal at (202) 205-1810.

SUPPLEMENTARY INFORMATION: Section 337 of the Tariff Act of 1930 
provides that if the Commission finds a violation it shall exclude the 
articles concerned from the United States:

unless, after considering the effect of such exclusion upon the 
public health and welfare, competitive conditions in the United 
States economy, the production of like or directly competitive 
articles in the United States, and United States consumers, it finds 
that such articles should not be excluded from entry.

19 U.S.C. 1337(d)(1). A similar provision applies to cease and desist 
orders. 19 U.S.C. 1337(f)(1).

    Therefore, the Commission is interested in further developing the 
record on the public interest in this investigation. Accordingly, 
members of the public are invited to file submissions of no more than 
five pages, inclusive of attachments, concerning the

[[Page 37641]]

public interest in light of the ALJ's recommended determination on 
remedy and bonding issued in this investigation on June 3, 2016. 
Comments should address whether the issuance of a limited exclusion 
order and cease and desist order would affect the public health and 
welfare in the United States, competitive conditions in the United 
States economy, the production of like or directly competitive articles 
in the United States, or United States consumers.
    In particular, the Commission is interested in comments that:
    (i) Explain how the articles potentially subject to the recommended 
orders are used in the United States;
    (ii) identify any public health, safety, or welfare concerns in the 
United States relating to the recommended orders;
    (iii) identify like or directly competitive articles that 
complainant, its licensees, or third parties make in the United States 
which could replace the subject articles if they were to be excluded;
    (iv) indicate whether complainant, complainant's licensees, and/or 
third party suppliers have the capacity to replace the volume of 
articles potentially subject to the recommended exclusion order and/or 
a cease and desist order within a commercially reasonable time; and
    (v) explain how the limited exclusion order and cease and desist 
order would impact consumers in the United States.
    Written submissions must be filed no later than by close of 
business on June 29, 2016.
    Persons filing written submissions must file the original document 
electronically on or before the deadlines stated above and submit eight 
true paper copies to the Office of the Secretary by noon the next day 
pursuant to section 210.4(f) of the Commission's Rules of Practice and 
Procedure (19 CFR 210.4(f)). Submissions should refer to the 
investigation number (Inv. No. 337-TA-956) in a prominent place on the 
cover page, the first page, or both. See Handbook for Electronic Filing 
Procedures, http://www.usitc.gov/secretary/fed_reg_notices/rules/ 
handbook_on_electronic_filing.pdf. Persons with questions regarding 
filing should contact the Secretary at (202) 205-2000.
    Any person desiring to submit a document to the Commission in 
confidence must request confidential treatment. All such requests 
should be directed to the Secretary to the Commission and must include 
a full statement of the reasons why the Commission should grant such 
treatment. See 19 CFR 201.6. Documents for which confidential treatment 
by the Commission is properly sought will be treated accordingly. A 
redacted non-confidential version of the document must also be filed 
simultaneously with any confidential filing. All non-confidential 
written submissions will be available for public inspection at the 
Office of the Secretary and on EDIS.
    This action is taken under the authority of Section 337 of the 
Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 
201.10, 210.46, and 210.50 of the Commission's Rules of Practice and 
Procedure (19 CFR 201.10, 210.46, 210.50).

    By order of the Commission.

    Issued: June 6, 2016.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2016-13688 Filed 6-9-16; 8:45 am]
BILLING CODE 7020-02-P